Abstract:Abstract Background Urine organic acids (UOA) analysis is an essential investigation for inborn errors of metabolism (IEMs). The vast majority of methods use gas chromatography mass spectrometry (GC-MS) and are only qualitative. Gas chromatography tandem mass spectrometry (GC-MS/MS) offers greater sensitivity and selectivity, and enables the combination of qualitative screening with quantitative analysis. We describe the development and preliminary validation results of a quantitative GC-MS/MS method. Methods Urine creatinine concentrations were measured (CobasPro, Roche Diagnostics) and normalized to 1.25 mmol/L. After internal standard addition, each urine specimen, calibration standard and QC were incubated with a hydroxylamine solution followed by a liquid-liquid extraction. Further sample concentration permitted the isolated UOA to be derivatized using N,O-bis(trimethylsilyl)trifluoroacetamine (BSTFA) with 1% chlorotrimethylsilane (TMCS) prior to injection. GC-MS/MS analysis was performed using a GC-MS-TQ8050 triple quadrupole system (Shimadzu) with a 30 m DB-5MS (Agilent J&W) capillary column (0.25 mm, ID of 0.25 μm). Split injection mode was deployed with an initial column temperature of 70°C. The mass spectrometer was operated in electron ionization (EI) and multiple reaction monitoring (MRM) modes. The linear concentration ranges of the targeted metabolites within the devised GC-MS/MS protocol were determined. Results The optimal temperature gradient for high-resolution UOA separations was derived and their respective retention times determined. MS/MS detection parameters were optimized to permit the identification of precursor and production ions for all (N = 38) derivatized UOA. Total analysis time was 33.8 min per injection. The achieved linear concentration ranges for each metabolite was respectively determined. Linear concentration ranges and correlation coefficients of representative UOA: 3-hydroxyisovaleric acid (range = 9 to 708 μmol/L, R2 = 0.9874); lactic acid (range = 15 to 751 μmol/L, R2 = 0.9936); 3-hydroxybutyric acid (range = 15 to 751 μmol/L, R2 = 0.9991); and 2-methyl-3-hydroxybutyric acid (range = 10 to 501 μmol/L, R2 = 0.9996). The correlation coefficients for all remaining UOA ranged from R2 = 0.9458 (4-hydroxyphenylpyruvic acid) to R2 = 0.9998 (3-methylglutanoic acid and ethylmalonic acid). Conclusion The devised GC-MS/MS protocol permits the unbiased identification and quantification of UOA used to investigate IEMs. The linear concentration ranges for all analytes were determined and are appropriate for monitoring these markers of inherited enzyme deficiencies. The analytical performance of this UOA GC-MS/MS method must be further validated and its diagnostic performance for selected IEMs characterized.

Robust classification and biomarker discovery of inherited metabolic diseases using GC-MS urinary metabolomics analysis combined with chemometrics

GC–MS urinary metabolomics analysis of inherited metabolic diseases and stable metabolic biomarker screening by a comprehensive chemometric method

Using random forest to detect multiple inherited metabolic diseases simultaneously based on GC-MS urinary metabolomics

Efficient Mass Spectrometric Characterization and Classification of Methylmalonic Aciduria Subtypes Through Urinary and Blood Metabolic Profiles Fusion

The Determination of Organic Acids in Urine with Gas Chromatography-Mass Spectrometry and Its Application in Clinical Diagnosis

Wide metabolite coverage LC-MS/MS assay for the diagnosis of inherited metabolic disorders in urine

Coupling bootstrap with synergy self-organizing map-based orthogonal partial least squares discriminant analysis: Stable metabolic biomarker selection for inherited metabolic diseases

A Simple Method for Rapid Screening and Diagnosis of Common Organic Acidemias: Quantitative Detection of Serum and Urine Organic Acid Profiles Based on Liquid Chromatography-Tandem Mass Spectrometry

Result of a Pilot External Quality Assessment Scheme for Clinical Diagnosis of Inherited Metabolic Disorders in China.

B-201 Development of a Quantitative Gas Chromatography Tandem Mass Spectrometry Method for Metabolic Profiling of Urine Organic Acids

Beyond one-against-all (OAA) and one-against-one (OAO): An exhaustive and parallel half-against-half (HAH) strategy for multi-class classification and applications to metabolomics

Integration of Machine Learning Techniques as Auxiliary Diagnosis of Inherited Metabolic Disorders - Promising Experience with Newborn Screening Data.

Straightforward Creation of Multishell Hollow Hybrids for an Integrated Metabolic Monitoring System in Disease Management.

A Fast and Non-Invasive Artificial Intelligence Olfactory-Like System That Aids Diagnosis of Parkinson's Disease

In Vitro Diagnostic Examination and Prognosis Surveillance by Hierarchical Heterojunction-Assisted Metabolic Analysis.

Analysis of Metabolic Changes in Endogenous Metabolites and Diagnostic Biomarkers for Various Diseases Using Liquid Chromatography and Mass Spectrometry

Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Application of gas chromatography-mass spectrometry analysis in the screening and diagnosis of organic acidurias

Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach

Urine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease

Urine and serum metabolic profiling combined with machine learning for autoimmune disease discrimination and classification